Literature DB >> 25091663

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life.

Nita Bhandari1, Temsunaro Rongsen-Chandola1, Ashish Bavdekar2, Jacob John3, Kalpana Antony4, Sunita Taneja1, Nidhi Goyal1, Anand Kawade2, Gagandeep Kang3, Sudeep Singh Rathore1, Sanjay Juvekar2, Jayaprakash Muliyil3, Alok Arya1, Hanif Shaikh2, Vinod Abraham3, Sudhanshu Vrati5, Michael Proschan6, Robert Kohberger7, Georges Thiry8, Roger Glass6, Harry B Greenberg9, George Curlin6, Krishna Mohan10, G V J A Harshavardhan10, Sai Prasad10, T S Rao11, John Boslego12, Maharaj Kishan Bhan13.   

Abstract

UNLABELLED: Rotavirus gastroenteritis is one of the leading causes of diarrhea in Indian children less than 2 years of age. The 116E rotavirus strain was developed as part of the Indo-US Vaccine Action Program and has undergone efficacy trials. This paper reports the efficacy and additional safety data in children up to 2 years of age. In a double-blind placebo controlled multicenter trial, 6799 infants aged 6-7 weeks were randomized to receive three doses of an oral human-bovine natural reassortant vaccine (116E) or placebo at ages 6, 10, and 14 weeks. The primary outcome was severe (≥11 on the Vesikari scale) rotavirus gastroenteritis. Efficacy outcomes and adverse events were ascertained through active surveillance. We randomly assigned 4532 and 2267 subjects to receive vaccine and placebo, respectively, with over 96% subjects receiving all three doses of the vaccine or placebo. The per protocol analyses included 4354 subjects in the vaccine and 2187 subjects in the placebo group. The overall incidence of severe RVGE per 100 person years was 1.3 in the vaccine group and 2.9 in the placebo recipients. Vaccine efficacy against severe rotavirus gastroenteritis in children up to 2 years of age was 55.1% (95% CI 39.9 to 66.4; p<0.0001); vaccine efficacy in the second year of life of 48.9% (95% CI 17.4 to 68.4; p=0.0056) was only marginally less than in the first year of life [56.3% (95% CI 36.7 to 69.9; p<0.0001)]. The number of infants needed to be immunized to prevent one episode of severe RVGE in the first 2 years of life was 40 (95% CI 28.0 to 63.0) and for RVGE of any severity, it was 21 (95% CI 16.0 to 32.0). Serious adverse events were observed at the same rates in the two groups. None of the eight intussusception events occurred within 30 days of a vaccine dose and all were reported only after the third dose. The sustained efficacy of the 116E in the second year of life is reassuring. CLINICAL TRIAL REGISTRY: The trial is registered with Clinical Trial Registry-India (# CTRI/2010/091/000102) and Clinicaltrials.gov (# NCT01305109).
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Gastroenteritis; Rotavirus; Vaccine efficacy

Mesh:

Substances:

Year:  2014        PMID: 25091663     DOI: 10.1016/j.vaccine.2014.04.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

2.  Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.

Authors:  Daniel E Velasquez; Baoming Jiang
Journal:  Hum Vaccin Immunother       Date:  2019-06-13       Impact factor: 3.452

3.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

4.  Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia.

Authors:  Eleanor Burnett; Jacqueline E Tate; Carl D Kirkwood; E Anthony S Nelson; Mathuram Santosham; A Duncan Steele; Umesh D Parashar
Journal:  Expert Rev Vaccines       Date:  2018-02-26       Impact factor: 5.217

5.  Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.

Authors:  Abdur Razzaque Sarker; Marufa Sultana; Rashidul Alam Mahumud; Robert Van Der Meer; Alec Morton
Journal:  Hum Vaccin Immunother       Date:  2017-12-12       Impact factor: 3.452

Review 6.  Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.

Authors:  Atefeh Afchangi; Tayebeh Latifi; Somayeh Jalilvand; Sayed Mahdi Marashi; Zabihollah Shoja
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

7.  Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.

Authors:  Annika Skansberg; Molly Sauer; Marissa Tan; Mathuram Santosham; Mary Carol Jennings
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

8.  The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.

Authors:  Yuxiao Wang; Jingxin Li; Pei Liu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

Review 9.  Current status of rotavirus vaccines.

Authors:  Ching-Min Wang; Shou-Chien Chen; Kow-Tong Chen
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

10.  Intussusception in Children Aged Less than Five years.

Authors:  Sanjay Mehendale; C P Girish Kumar; S Venkatasubramanian; T Prasanna
Journal:  Indian J Pediatr       Date:  2016-05-23       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.